Parathyroid Disorders. Группа авторов

Чтение книги онлайн.

СКАЧАТЬ C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE: A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995;11:389–394.

16Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A: Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005;19:2603–2609.

17Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O’Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM: Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 2003;63:8022–8028.

18Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010;54:106–109.

19Bordier P, Ryckewart A, Gueris J, Rasmussen H: On the pathogenesis of the so-called idiopathic hypercalciuria. Am J Med 1977;63:398–409.

20Palmieri S, Eller-Vainicher C, Cairoli E, Morelli V, Zhukouskaya VV, Verga U, Filopanti M, Vicentini L, Ferrero S, Spada A, Chiodini I: Hypercalciuria may persist after successful parathyroid surgery and it is associated with parathyroid hyperplasia. J Clin Endocrinol Metab 2015;100:2734–2742.

21Maruani G, Hertig A, Paillard M, Houillier P: Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88:4641–4648.

22Balenga N, Azimzadeh P, Hogue JA, Staats PN, Shi Y, Koh J, Dressman H, Olson JA Jr: Orphan adhesion GPCR GPR64/ADGRG2 is overexpressed in parathyroid tumors and attenuates calcium-sensing receptor-mediated signaling. J Bone Miner Res 2017;32:654–666.

23Díaz-Soto G, Romero E, Castrillón JL, Jauregui OI, de Luis Román D: Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism. Horm Metab Res 2016;48:163–168.

24Díaz-Soto G, Romero E, Pérez-Castrillón JL, Jauregui OI, de Luis Román D: Parathyroid hormone polymorphism RS6254 is associated with the development and severity of osteoporosis in asymptomatic but not normocalcemic hyperthyroidism. Horm Metab Res 2016;48:828–833.

25Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.

26Forster J, Monchik JM, Martin HF: A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium. Surgery 1998;104:1137–1142.

27Som M, Stroup JS: Primary hyperparathyroidism and pregnancy. Proc Bayl Univ Med Cent 2011;24:220–223.

28Eisner B, Ahn J, Stoller M: Differentiating primary from secondary hyperparathyroidism in stone patients: the “Thiazide challenge”. J Endourol 2009;23:191–192.

29Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ, Weiss M: Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. J Endocrinol Invest 2003;26:327–332.

30Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R: Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J Nephrol 2016;29:71–78.

31Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001–3005.

32Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F: Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012;2012:128352.

33Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, Katsalira K, Lyritis GP: Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 2006;91:1748–1753.

34Díaz-Soto G, de Luis Román D, Jauregui OI, Briongo L, Romero E, Pérez-Castrillón JL: Trabecular bone score in patients with normocalcemic hyperparathyroidism. Endocr Pract 2016;22:703–707.

35Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, Liang J, Li L, Lin W, Lin L, Shi L, Cai L, Wen J: Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 2015;100:2420–2424.

36Corbetta S, Mantovani G, Spada A: Metabolic syndrome in parathyroid diseases. Front Horm Res 2018;49:144–159.

37Mesquita PN, Dornelas Leão Leite AP, Chagas Crisostomo SD, Veras Filho E, da Cunha Xavier L, Bandeira F: Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc Health Risk Manag 2017;13:225–229.

38Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S: Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 2017;177:R297–R308.

39van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA: Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 2013;165:655–664.

40Billington EO, Gamble GD, Reid IR: Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. Bonekey Rep 2016;5:852.

41Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F: Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 2012;42:419–422.

СКАЧАТЬ